Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
This study, called ALBAN, is for people in Europe with a type of bladder cancer that hasn't spread into the muscle wall (non-muscle invasive bladder cancer) and is considered high-risk. Participants have never had a specific treatment called BCG before. The study aims to see if combining the standard treatment, BCG, with a newer drug called atezolizumab is more effective than BCG alone in stopping the cancer from returning. Half of the participants receive BCG only, and the other half receive BCG plus atezolizumab. Researchers will track how long participants remain free from cancer events to determine which approach works best. This is a Phase 3 trial, meaning it's a large study to confirm the effectiveness and safety of the new treatment combination.
במבט חטוף
על מה המחקר הזה?
This study, called ALBAN, is designed for people who have been diagnosed with a type of early bladder cancer. This means the cancer has not grown deep into the bladder muscle. For some patients, this type of bladder cancer is considered 'high-risk,' meaning there's a higher chance it could come back or spread if not treated effectively. This particular study is for people who haven't had a specific bladder cancer treatment called BCG before.
The main aim of ALBAN is to see if a new combination of treatments works better than the standard treatment. The standard treatment involves giving a medicine called BCG directly into the bladder. The study is comparing this standard BCG treatment with a new approach: giving BCG along with another drug called atezolizumab. Atezolizumab is a type of immunotherapy that helps your body's immune system fight cancer. By comparing these two approaches, researchers hope to find out if adding atezolizumab makes the treatment more effective at preventing the cancer from returning.
This is a 'Phase 3' study, which means it's a large trial involving many people. The goal is to get clear answers about whether the new combination treatment is better than the existing treatment for this specific group of bladder cancer patients. The study is being carried out in different hospitals across Europe.
נקודות עיקריות
- This study compares a new combination treatment for early bladder cancer.
- It tests BCG treatment alone versus BCG plus atezolizumab.
- It's for people with high-risk, early bladder cancer who haven't had BCG before.
- The main aim is to see which treatment prevents the cancer from returning more effectively.
- This is a Phase 3 study, meaning it's a large trial to confirm the benefits and safety.
- Results could help improve future treatments for this type of cancer.
מי עשוי להיות זכאי?
To join this study, participants needed to be at least 18 years old and have a specific type of high-risk, early-stage bladder cancer that hasn't spread into the muscle. Importantly, they must not have had BCG treatment for this cancer before. The doctors also needed to confirm the cancer diagnosis from tissue collected during surgery.
Before taking part, participants would have had scans (like CT or MRI) to make sure the cancer hadn't spread to other parts of their body. They also needed to be generally well, meaning they could carry out most daily activities without too much difficulty. Their blood pressure needed to be within a healthy range, and routine blood tests (checking blood counts and organ function) had to show healthy results.
For some patients, a second operation to remove the tumor might have been needed before they could join, to make sure all visible cancer was removed and to confirm the diagnosis. If you meet these general criteria, your doctor could then check the more detailed requirements.
האם מחקר זה יכול להתאים לך?
ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.
- אני בן 18 או יותר.
- I have high-risk bladder cancer that has not spread into the bladder muscle.
- I have never received BCG treatment for my bladder cancer.
- I am generally well and active.
- My recent scans show the cancer has not spread to other organs.
- My blood tests are within healthy ranges for my organs and blood counts.
מה כרוך בהשתתפות?
If you were eligible and chose to take part in this study, you would have been randomly assigned to one of two treatment groups: either receiving BCG alone or receiving BCG plus atezolizumab. This means a computer decides which treatment you get, much like flipping a coin, to ensure fairness.
Both treatments involve a course of medication. You would have had regular appointments at the hospital for these treatments and to have various check-ups. These check-ups would involve physical examinations, blood tests, and possibly scans to monitor your health and how the treatment is working. Doctors would also carefully check for any side effects.
The study would involve regular follow-up over a period of time to track your progress and see how long you remain free from cancer returning. The total duration of active treatment and follow-up would be explained in detail by your medical team.
סיכונים ותועלות פוטנציאליים
מיקומים (38)
- Groupe Jolimont - Hôpital de Jolimontמיקוד מאומתHaine-Saint-Paul, Belgium
- AZ Delta - Campus Rumbekeמיקוד מאומתRoeselare, Belgium
- Centre Hospitalier Universitaire Angersמיקוד מאומתאנז'ה, צרפת
- Centre Hospitalier Universitaire Bordeauxמיקוד מאומתבורדו, צרפת
- Hôpital G. Montpiedמיקוד מאומתקלרמון-פראן, צרפת
- Clinique Claude Bernardמיקוד מאומתErmont, France
- CHU Grenobleמיקוד מאומתגרנובל, צרפת
- Hôpital privé Toulon - Sainte Margueriteמיקוד מאומתHyères, France
- Hôpital du Kremlin-Bicêtreמיקוד מאומתLe Kremlin-Bicêtre, France
- Hôpital Saint Vincentמיקוד מאומתליל, צרפת
- Hôpital privé de la Louvièreמיקוד מאומתליל, צרפת
- Hôpital Saint Philibertמיקוד מאומתLomme, France
שאלות נפוצות
What is Non-Muscle Invasive Bladder Cancer?
It's an early form of bladder cancer where the cancer cells have not grown into the deeper muscle layer of the bladder wall.
What is BCG bladder instillation?
BCG is a medicine, often used as an immunotherapy, that's put directly into your bladder through a small tube. It helps your immune system fight the cancer.
What is atezolizumab?
Atezolizumab is an immunotherapy drug, usually given into a vein, that helps your body's own immune system to recognise and attack cancer cells more effectively.
What does 'high-risk' mean in this context?
It means there's a higher chance of the cancer coming back or progressing if not treated effectively, often due to the type or grade of the cancer cells.
Why is this not available to everyone?
Because it's a new combination treatment being tested, it's only available to people who meet specific criteria within the clinical study to assess its safety and effectiveness properly.
כיצד לגלות עוד
תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.
דיון
דיון קהילתי
מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.